Company Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body.
Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jan 2, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Daniel Passeri |
Contact Details
Address: 40 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617 949 2680 |
| Website | cuebiopharma.com |
Stock Details
| Ticker Symbol | CUE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645460 |
| CUSIP Number | 22978P106 |
| ISIN Number | US22978P1066 |
| Employer ID | 47-3324577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Passeri J.D., M.Sc. | Chief Executive Officer and Director |
| Kerri-Ann Millar CPA | Chief Financial Officer |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo J. Chaparro Ph.D. | Co-Founder and Senior Advisor |
| Dr. Steven C. Almo Ph.D. | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| Colin G. Sandercock J.D., MSE | Senior Vice President, General Counsel and Secretary |
| Dr. Matteo Levisetti M.D. | Chief Medical Officer |
| Lucinda Warren | Chief Business Officer |
| Dr. Daniel G. Baker M.D., Ph.D. | Interim Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 31, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 21, 2025 | SCHEDULE 13G/A | Filing |
| Mar 12, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Dec 16, 2024 | UPLOAD | Filing |
| Dec 5, 2024 | UPLOAD | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |